Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

Published:2022-07-19 Issue:5 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Maldonado Ivette¹,Plata Manuel²,Gonzalez Mauricio³,Correa Alfonso⁴,Nossa Claudia⁵,Giuliano Anna R.⁶^ORCID,Joura Elmar A.⁷^ORCID,Ferenczy Alex⁸,Ronnett Brigitte M.⁹,Stoler Mark H.¹⁰,Jin Zhou Hao¹¹,Joshi Amita¹¹,Das Rituparna¹¹,Bautista Oliver¹¹,Group Thomas¹¹,Luxembourg Alain¹¹,Saah Alfred¹¹,Buchwald Ulrike Kirsten¹¹^ORCID

Affiliation:

1. Department of Obstetrics & Gynaecology, Fundación Santa Fe de Bogotá, Bogotá, Colombia

2. Department of Gynaecology, Fundación Cardioinfantil, Bogotá, Colombia

3. Ginecologo Oncologo, Instituto Nacional de Cancerología, Bogotá, Colombia

4. Clínica del Country, Bogotá, Colombia

5. Cafam, Bogotá, Colombia

6. Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

7. Department of Obstetrics & Gynaecology, Medical University of Vienna, Vienna, Austria

8. Department of Gynecologic Pathology and Cytopathology, University Health Center and Jewish General Hospital, Montreal, Quebec, Canada

9. Johns Hopkins Gynecologic Pathology Consultation Service, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

10. Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA

11. Merck & Co., Inc, Rahway, NJ, USA

Funder

Merck Sharp & Dohme Corp

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2022.2078626

Reference33 articles.

1. Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women — United States, 2008 and 2016

2. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study

3. Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men

4. Genital Wart Recurrence Among Men Residing in Brazil, Mexico, and the United States

5. An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of individual socioeconomic and health-related characteristics associated with human papillomavirus vaccination initiation and vaccination series completion among adult females: A comprehensive systematic evidence review with meta-analysis;Vaccine;2024-09

2. Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies;Journal of Medical Virology;2024-09

3. Cancer-preventing vaccination programs in prison: promoting health equity in Europe;The Lancet Regional Health - Europe;2024-08

4. Estimation of self‐funded human papillomavirus vaccine recipients from Japan's previously assumed “unvaccinated generation”;Cancer Science;2024-07-11

5. Opportunities and challenges for human papillomavirus vaccination in China;Human Vaccines & Immunotherapeutics;2024-04-04